Financial Performance - The group's revenue increased by approximately RMB 171.5 million or 20.9% to approximately RMB 992.0 million for the year ended December 31, 2022[2]. - Gross profit rose by approximately RMB 143.2 million or 24.8% to approximately RMB 720.9 million compared to the previous year[2]. - EBITDA increased by approximately RMB 143.1 million or 50.8% to approximately RMB 424.9 million for the year ended December 31, 2022[2]. - Profit attributable to equity holders increased by approximately RMB 93.6 million or 49.9% to approximately RMB 281.2 million[2]. - Total comprehensive income for the year was RMB 289.1 million, compared to RMB 181.4 million in the previous year[6]. - The group's profit before tax reached RMB 281,218,000 in 2022, up from RMB 187,643,000 in 2021, representing a growth of 49.9%[28]. - The net profit for the year ended December 31, 2022, was approximately RMB 281.2 million, an increase of about RMB 93.6 million or 49.9% compared to RMB 187.6 million for the year ended December 31, 2021[66]. Revenue Breakdown - Revenue from external customers in mainland China for 2022 was RMB 984,383 thousand, an increase from RMB 817,130 thousand in 2021, representing a growth of approximately 20.5%[17]. - Total revenue for 2022 was RMB 992,014 thousand, compared to RMB 820,543 thousand in 2021, indicating a year-over-year increase of about 20.9%[21]. - Revenue from a major customer (Customer A) accounted for RMB 101,466 thousand in 2022, up from RMB 95,890 thousand in 2021, which is an increase of approximately 5.5%[19]. - Revenue from the sales of Jin Sang Zi throat lozenges (OTC) was approximately RMB 904.6 million, an increase of approximately RMB 165.4 million or 22.4% compared to RMB 739.2 million for the previous year[55]. Assets and Liabilities - Current liabilities totaled RMB 734.6 million, an increase from RMB 579.2 million in the previous year[7]. - Total assets less current liabilities amounted to RMB 1,564.7 million, up from RMB 1,374.0 million in the previous year[10]. - Cash and cash equivalents increased to RMB 895.5 million from RMB 722.8 million in the previous year[9]. - The company's total equity attributable to equity holders increased to RMB 1,539.1 million from RMB 1,365.1 million[11]. - Trade receivables increased to RMB 620,338,000 in 2022 from RMB 417,179,000 in 2021, reflecting a growth of 48.6%[29]. - The aging analysis of trade receivables shows that RMB 23,586,000 was within three months, up from RMB 20,771,000 in 2021[31]. - Trade payables rose to RMB 25,313,000 in 2022, compared to RMB 21,829,000 in 2021, marking an increase of 15.3%[32]. - The group had bank loans repayable within one year amounting to RMB 272,586,000 in 2022, an increase from RMB 234,597,000 in 2021[35]. Expenses and Costs - The total income tax expense for 2022 was RMB 94,775,000, compared to RMB 49,204,000 in 2021, indicating an increase of 92.5%[25]. - The financial costs for 2022 amounted to RMB 10,294,000, an increase of 29.0% from RMB 7,975,000 in 2021[27]. - The company's sales and distribution expenses were approximately RMB 279.0 million, an increase of approximately RMB 17.4 million or 6.7% compared to RMB 261.6 million for the previous year[61]. - The employee costs for the year ended December 31, 2022, were approximately RMB 80.4 million, compared to RMB 79.4 million for the same period in 2021[70]. Dividends - The board proposed a final dividend of HKD 0.36 per share, subject to approval at the upcoming annual general meeting[2]. - The proposed final dividend for 2022 is HKD 0.36 per share, which is double the HKD 0.18 per share proposed for 2021, totaling RMB 237,743,000 compared to RMB 108,802,000[26]. Product Development and Market Presence - The flagship product, Jin Sang Zi Throat Lozenges (OTC), accounted for approximately 91.2% of the total revenue for the year ended December 31, 2022[41]. - Jin Sang Zi Throat Treasure series products contributed about 8.2% to the total revenue for the year ended December 31, 2022[42]. - Other products, including Ginkgo Biloba tablets, represented approximately 0.6% of the total revenue for the year ended December 31, 2022[43]. - The company launched a new product, Jin Sang Zi Intestinal Treasure, in June 2022, which is a proprietary prebiotic aimed at enhancing gut health[44]. - The company aims to improve the health of Chinese consumers with its newly developed active probiotics, which have received six patents[44]. - The company’s sales revenue showed significant improvement in 2022, attributed to the recognition of its products in the treatment of throat symptoms related to COVID-19[40]. - As of December 31, 2022, the company has exported its products to 22 countries and regions, with new additions including France, Spain, the Netherlands, Italy, and Ireland in 2022, and Luxembourg, Croatia, and Estonia in early 2023[47]. - The distribution network covers all provinces, autonomous regions, and municipalities in China, with significant revenue derived from sales to distributors as of December 31, 2022[48]. - The company has established a presence in 53 countries and regions globally, including the US, Canada, Japan, and Australia, with the OTC product gaining registration in Malaysia, set to enter mainstream hospitals and clinics in Q2 2023[49]. Corporate Governance and Compliance - The company has adopted a corporate governance code to ensure shareholder rights and enhance corporate value and accountability[79]. - All directors have complied with the standard code regarding securities trading for the year ended December 31, 2022[80]. - The audit committee reviewed the accounting principles and policies, as well as the audited consolidated financial statements for the year ended December 31, 2022, and found the existing risk management and internal control systems to be effective and adequate[81]. - No purchase, sale, or redemption of the company's listed securities occurred during the year ended December 31, 2022[81]. - The annual report for the year ended December 31, 2022, will be sent to shareholders and published on the stock exchange and the company's website[81].

金嗓子控股集團有限公司 GOLDEN THROAT HOLDINGS GROUP COMPANY LIMITED ( 於 開曼群島註冊成立的有限公司) 股份代號 : 06896 中 期 報 告 2022 | --- | --- | --- | --- | --- | --- | --- | --- | |----------|---------------------------------------------------|-------|------------------------|--------------|-----------|-----------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | @ TREN COREMY 场会益生元(M-R) PREBIOTICS 貿易公開 | | | | | 행（ 麟翔 | | | | | | @ 图片期的酒 st 曲宫片 | ...

Financial Performance - The group's revenue increased by approximately RMB 173.6 million or 26.8% to approximately RMB 820.5 million compared to the year ended December 31, 2020[8]. - The group's gross profit rose by approximately RMB 102.1 million or 21.5% to approximately RMB 577.7 million compared to the year ended December 31, 2020[8]. - The group's EBITDA increased by approximately RMB 48.5 million or 20.8% to approximately RMB 281.8 million compared to the year ended December 31, 2020[8]. - The profit attributable to equity holders increased by approximately RMB 33.5 million or 21.7% to approximately RMB 187.6 million compared to the year ended December 31, 2020[8]. - The group's revenue for the year ended December 31, 2021, was approximately RMB 820.5 million, an increase of about RMB 173.6 million or 26.8% compared to RMB 646.9 million for the year ended December 31, 2020[30]. - Revenue from the sales of Jin Sangzi throat lozenges (OTC) was approximately RMB 739.2 million, up RMB 157.4 million or 27.1% from RMB 581.8 million in the previous year, indicating recovery to pre-COVID-19 levels[30]. - The sales revenue from Jin Sangzi throat treasure series products was approximately RMB 71.7 million, an increase of RMB 18.0 million or 33.5% compared to RMB 53.7 million in the previous year[31]. - The group's gross profit for the year ended December 31, 2021, was approximately RMB 577.7 million, an increase of RMB 102.1 million or 21.5% from RMB 475.6 million in the previous year[35]. - The net profit for the year ended December 31, 2021, was approximately RMB 187.6 million, an increase of about RMB 33.5 million or 21.7% compared to RMB 154.1 million for the year ended December 31, 2020[42]. - The total comprehensive income for the year was RMB 181,363 thousand, compared to RMB 143,282 thousand in 2020, marking a growth of 26.6%[166]. Dividends and Shareholder Returns - The company plans to pay a final dividend of HKD 0.18 per share for the year ended December 31, 2021, subject to shareholder approval[8]. - The company reported a final dividend of HKD 0.18 per share for the year ended December 31, 2021, subject to shareholder approval at the annual general meeting on May 13, 2022[62]. - The company maintains a stable dividend policy, prioritizing consistent cash dividend distribution as a key profit allocation goal[65]. - The company declared dividends of RMB 36,562,000 for the year, a decrease from RMB 77,069,000 in the previous year, representing a reduction of about 52.5%[170]. Research and Development - The new pharmaceutical production and R&D base has been completed with a total area of approximately 60,000 square meters, including R&D center, production plant, warehouse, and administrative office[10]. - A new land parcel of 48 acres has been selected for the second phase of the new base, expected to have a construction area of approximately 50,000 square meters for food production and R&D center[10]. - The company aims to develop new products such as gene drugs, traditional Chinese medicine formulas, and specialty health foods through its new R&D platforms[10]. - The company plans to continue optimizing its product system and enhancing organizational capabilities in 2022, focusing on consumer demand and digital marketing[19]. - The company will enhance its production capacity, expand its product portfolio, and strengthen R&D capabilities to promote synergy among different product segments[48]. Market Position and Brand Recognition - The company has been recognized as the top brand in the "Traditional Chinese Medicine - Throat Category" in the 2021 statistics of non-prescription drug enterprises and products in China[9]. - The company is focused on achieving breakthroughs in the pharmaceutical and fast-moving consumer goods sectors in 2022[11]. - The company is a leading manufacturer of throat lozenges in China, ranking first in the "Traditional Chinese Medicine - Throat Category" in 2021[18]. - The company aims to strengthen its leading position in the throat lozenge market and expand its market share in the pharmaceutical and food sectors in China[48]. Operational Challenges and Responses - The company actively responded to the COVID-19 pandemic by resuming production and donating anti-epidemic materials[18]. - In 2020, the company faced challenges due to the pandemic, with a decline in offline sales channels such as pharmacies and supermarkets[18]. - The sales situation has recovered to pre-COVID-19 levels as of 2021, despite ongoing pandemic challenges[25]. - In 2021, the company achieved a recovery in sales to pre-COVID-19 levels, supported by the overall stabilization of the pandemic situation in China[19]. Financial Position and Assets - As of December 31, 2021, the company's current assets net value was approximately RMB 855.7 million, compared to RMB 696.4 million as of December 31, 2020[43]. - Total interest-bearing bank and other borrowings as of December 31, 2021, amounted to approximately RMB 235.0 million, an increase of RMB 82.5 million compared to RMB 152.5 million as of December 31, 2020[43]. - The company's asset-liability ratio increased from approximately 12.5% as of December 31, 2020, to approximately 17.2% as of December 31, 2021[43]. - The company reported a significant increase in inventory, which rose to RMB 64,963 thousand from RMB 38,843 thousand in 2020, a growth of 67%[167]. - The total equity as of December 31, 2021, was RMB 1,365,143 thousand, compared to RMB 1,220,342 thousand in 2020, reflecting an increase of 11.9%[168]. Governance and Management - The company has established a compensation committee to determine the compensation policy based on operational performance and market practices[83]. - The board of directors consists of nine members, including five executive directors, one non-executive director, and three independent non-executive directors[119]. - The company has complied with all applicable code provisions of the corporate governance code as of December 31, 2021[117]. - The independent non-executive directors have confirmed their independence according to the listing rules[119]. - The company encourages directors to seek independent professional advice at the company's expense when fulfilling their duties[129]. Compliance and Risk Management - The company has complied with all applicable laws and regulations, with no significant violations reported as of December 31, 2021[152]. - The company has established appropriate arrangements for employees to raise concerns regarding financial reporting and internal controls[138]. - The audit committee reviewed the effectiveness of the risk management and internal control systems and deemed them effective and adequate for the year ended December 31, 2021[142]. - The company has not purchased insurance for its directors against legal actions, believing that regular communication with management can effectively handle potential claims[141]. Future Outlook and Strategic Plans - The company aims to establish a new growth logic for its products to ensure healthy development in the future[19]. - The company plans to allocate approximately HKD 189.98 million (about 21% of the IPO proceeds) for transforming its headquarters into a food production plant and R&D center[52]. - The company intends to improve brand awareness through effective targeted marketing and continue to expand its distribution network[48]. - The company has not utilized any IPO proceeds for the establishment of the traditional Chinese medicine processing base as of December 31, 2021[52].

LOEN 金嗓子控股集團有限公司 GOLDEN THROAT HOLDINGS GROUP COMPANY LIMITED (於開曼群島註冊成立的有限公司) 股份代號 : 06896 中 期 報 告 2021 Golden Throat ozenge E 国药准字Z45020908 (536) 混合產品 F8C® C008001 are of Callery 厂西金额子集团创始人 工假的 本省 OTC (无使捷) 都乐会) 0 GOLDEN THROAT CANDY 广播会体手作风品发展 Golden ( 16) 国药准字Z45020908 let Golden Throat Pian .9 P P # .9 A P B 11 15:41 p Danqi 日本河北日 TRYXES . P B O D P O D B 目錄 2 公司簡介 3 公司資料 5 財務摘要 6 釋義 8 管理層討論及分析 24 企業管治╱其他資料 29 中期簡明綜合損益表 30 中期簡明綜合全面收益表 中期簡明綜合財務狀況表 31 33 中期簡明綜合權益變動表 中期簡明綜合現金流表 35 37 中期簡明綜合財務報表附註 公司簡介 金嗓子 ...

GOLDE 金嗓子控股集團有限公司 GOLDEN THROAT HOLDINGS GROUP COMPANY LIMITED (根據開曼群島法律註冊成立的成員責任有限公司) 股份代號 : 06896 GOLDEN THROAT CANDY "两会味子छ候品有限公司 g 国药准字Z45020908 FSC 混合產品 通自負責任的 和林資源的影張 F8C® C008061 2020 年度報告 ord er 子供 元龍龍之路 Golden f Golden den Throat Lozenga r as a le 全球子供官 1288888888 C 1 0 国药难学Z45020904 回 GOLDEN THROAT CANDY E lings and and 杏 叶 inxtngye Pic 8 22 v 8A. 文]班 | --- | --- | --- | --- | --- | |-------|-------|-------|-------|-------------------------------| | | | | | | | | | | | | | | | | | | | | | | | 目錄 | ...

GOLDE 金嗓子控股集團有限公司 GOLDEN THROAT HOLDINGS GROUP COMPANY LIMITED (於開曼群島註冊成立的有限公司) 股份代號 : 06896 2020 GOLDEN THROAT CANDY 网络唯字220027939 广西会吸子深使品有限公司 OTC 哟( Golden Golden Throat Lozenge 6片x2 国 国 药 准 字Z45020908 (36片 সা & 物 盘记 值 官 澳 t was (16 ब Dangi April 88 88 80 混合產品 F8C® C008001 正郎沖빵 ( 簡易 ) 本站 文母 ( 音樂 :田园 国药准字Z20027939 德 Yinxingye Pian loe 0 西 南 南 (36片) er 国药准字Z45020908 Pian 周圍所監的 anqi 股 旅客網 報 參見 參 東大大 東京大學 8 STANT IS @ 目錄 2 3 6 35 37 公司簡介 公司資料 5 財務摘要 釋義 8 管理層討論及分析 23 29 30 31 33 企業管治╱其他資料 中期簡明綜合損益表 中期簡明綜合全面收益 ...

金嗓子控股集團有限公司 GOLDEN THROAT HOLDINGS GROUP COMPANY LIMITED (根據開曼群島法律註冊成立的成員責任有限公司) 股份代號 : 06896 年度報告 2019 OLDEN THROAT CANDY - 2011 KENSE 展镇品有限公司 Golden Throat Lozenge 228节 FSC 混合產品 您自负责任的 麻辣買部的概張 F8C® C008061 13 35 GOLDEN THROAT CANDY Cden Gol Golden Throat OTC KPHI 0 le 都乐 于保健品折散な可 SC 0 0 0 11 2 登录 22.8克 目錄 2 公司簡介 3 公司資料 5 財務摘要 6 主席報告 9 釋義 13 管理層討論及分析 29 董事及高級管理層 34 董事會報告 56 企業管治報告 73 獨立核數師報告 79 綜合損益表 80 綜合全面收益表 81 綜合財務狀況表 83 綜合權益變動表 85 綜合現金流表 87 財務報表附註 164 五年財務概要 公司簡介 | --- | --- | |----------------------- ...

金嗓子控股集團有限公司 GOLDENTHROAT HOLDINGS GROUP COMPANY LIMITED ( 於 開曼群島註冊成立的有限公司) 股份代號 : 06896 0 | --- | --- | --- | --- | --- | --- | --- | |--------|---------------------------------------------------------------|----------------------|-------|-------|-------|-------| | | | | X | | | | | | | | | | | | | 都乐含 | 会杀子也 都乐 润 喝 都乐含 DULE NODO 不合成語冷食量，243 | | | | | | | 清新ł | 清凉爽 | Gold | | | | | | 登录 | . 净含量: 2 | Golden Throa Lozenge | | | | | older of the ( G FSC 混合產品 ® OTC the rident mere a seen a was beared to the str ...

金嗓子控股集團有限公司 GOLDEN THROAT HOLDINGS GROUP COMPANY LIMITED (於開曼群島註冊成立的有限公司) 股份代號 : 06896 年度報告 2018 | --- | --- | --- | --- | --- | --- | --- | |-------------|-----------------------------|-----------------------|-------|--------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | 全球子 | | | | | | | 都乐含 都乐 | 都乐润够 DULE NOIX 千余旅購 | | | THROAT | | | | | | Golden Throat Lozenge | | | | | FSC 混合產品 间直负责任的 且林資源的题强 F8C® C008061 e OTO 4子集团创始人- 江假珍 Golden (无菌婕) 都乐含片 Ci GOLDEN THROAT Golden Throal 厂商企除守-保 ...